0 Items
Select Page

Escherichia coli

E. coli is a bacterial species that normally resides in the intestines of people and animals. However, some types of E. coli, particularly E. coliO157:H7, can cause intestinal infection. E. coli O157:H7 and other strains that cause intestinal sickness are called Shiga toxin–producing E. coli (STEC) after the toxin they produce.

Symptoms of intestinal infection include diarrhoea, abdominal pain, and fever. More severe cases can lead to bloody diarrhoea, dehydration, or even kidney failure. People with weakened immune systems, pregnant women, young children, and older adults are at increased risk for developing these complications.

To support research into E. coli infection, The Native Antigen Company has developed an E. coli antibody that is highly specific to the O157:H7 strain.

E. coli Background

E. coli is a gram-negative, rod-shaped, facultative, anaerobic bacterium. Most strains of E. coliare harmless, but some are pathogenic to humans. Some of these pathogenic strains of E. coliproduce Shiga toxins – potent bacteriophage encoded cytotoxins. Shiga toxin-producing E. coli (STEC) are a common causes of severe food poisoning in humans worldwide.

Cattle and other ruminants are natural reservoirs of E. coli O157:H7, where the bacteria exists in the animals’ intestine as part of its normal intestinal flora. Outside of the natural host, E. coli O157:H7 can survive in diverse environments including water, soil and food. In particular, E. coli O157:H7 can survive in meat that has been contaminated with faecal matter and undercooked beef. E. coli O157:H7 bacteria can thrive at temperatures ranging from 7 – 50oC, so that thorough cooking of meats is essential to destroy it. Other foods have been linked to E. coli O157:H7 outbreaks including unpasteurised milk, cured meats, bean sprouts and leafy vegetables, which have all been associated with faecal contamination.

E. coli O157 can infect individuals from all age groups, is resistant to stomach acids and is highly infectious. In humans, the ingested bacterium invades and colonises the intestinal mucosa. Symptoms of E. coli O157 infection include stomach cramps, haemorrhagic diarrhoea and vomiting. Haemolytic uremic syndrome (HUS) may also occur in severe cases of infection, which can result in life threatening renal failure.

Pathogenic strains of E. coli acquire virulence factors through various means including plasmids and bacteriophages. Several virulence factors are associated with E. coli O157:H7, including Shiga toxins, putative virulence plasmid O157 (pO157) and a pathogenicity island referred to as the locus of enterocyte effacement (LEE). Together, these virulence factors are currently thought to be responsible for the pathogenic nature of E. coli O157:H7 (Lim JY).

References

  1. Lim JY, Yoon J, Hovde CJ. 2010.A brief overview of Escherichia coli O157:H7 and its plasmid O157. J Microbiol Biotechnol. Jan;20(1):5-14

E. coli Antibodies

The Native Antigen Company offers a high-specificity monoclonal antibody to the Escherichia coli O157:H7 strain. Our E. coli antibody has been extensively tested to show that it does not cross-react with a wide range of other, related E. coli strains or bacteria responsible for gastrointestinal infections.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Challenges to Effective Yellow Fever Diagnostics

Yellow fever is a haemorrhagic viral disease, transmitted by infected mosquitos in Africa and South America. While an effective vaccine is available, inadequate vaccination of endemic areas has made diagnostics a necessity to controlling ongoing outbreaks. However,...

Five Methods You Can Use to Overcome Zika-Dengue Cross-Reactivity

Cross-reactivity between the Zika and Dengue viruses in serological assays is one of the biggest challenges faced by the epidemiologists, academics and pharmaceutical companies trying to control the Zika epidemic, as it brings the quality and reliability of diagnostic...

Why Zika virus’s cross-reactivity with Dengue might be hampering your research

Given the impact of Zika, it’s no surprise that a global contingent of epidemiologists, academic researchers, and pharmaceutical companies are striving to develop effective disease control measures and treatments. One challenge currently hindering the...

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 3 =

Live Customer Feedback